Literature DB >> 19615428

Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin.

Kristy M Nicks1, Daniel S Perrien, Nisreen S Akel, Larry J Suva, Dana Gaddy.   

Abstract

There is both cellular and physiological evidence demonstrating that both Activins and Inhibins regulate osteoblastogenesis and osteoclastogenesis, and regulate bone mass in vivo. Although Activins and Inhibins were initially isolated from the gonad, Activins are also produced and stored in bone, whereas Inhibins exert their regulation on bone cell differentiation and metabolism via endocrine effects. The accumulating data provide evidence that reproductive hormones, distinct from classical sex steroids, are important regulators of bone mass and bone strength. Given the well described dominant antagonism of Inhibin over Activin, as well as over BMPs and TGFbeta, the gonadally derived Inhibins are important regulators of locally produced osteotrophic factors. Thus, the cycling Inhibins in females and diurnal changes in Inhibin B in males elicit temporal shifts in Inhibin levels (tone) that de-repress the pituitary. This fundamental action has the potential to de-repress locally stimulated changes in osteoblastogenesis and osteoclastogenesis, thereby altering bone metabolism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19615428      PMCID: PMC2951729          DOI: 10.1016/j.mce.2009.07.001

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  108 in total

1.  A novel role for bone morphogenetic proteins in the synthesis of follicle-stimulating hormone.

Authors:  H J Huang; J C Wu; P Su; O Zhirnov; W L Miller
Journal:  Endocrinology       Date:  2001-06       Impact factor: 4.736

2.  FSH directly regulates bone mass.

Authors:  Li Sun; Yuanzhen Peng; Allison C Sharrow; Jameel Iqbal; Zhiyuan Zhang; Dionysios J Papachristou; Samir Zaidi; Ling-Ling Zhu; Beatrice B Yaroslavskiy; Hang Zhou; Alberta Zallone; M Ram Sairam; T Rajendra Kumar; Wei Bo; Jonathan Braun; Luis Cardoso-Landa; Mitchell B Schaffler; Baljit S Moonga; Harry C Blair; Mone Zaidi
Journal:  Cell       Date:  2006-04-21       Impact factor: 41.582

3.  Induction of differentiation of the human promyelocytic cell line HL-60 by activin/EDF.

Authors:  R Yamada; T Suzuki; M Hashimoto; Y Eto; K Shiokawa; M Muramatsu
Journal:  Biochem Biophys Res Commun       Date:  1992-08-31       Impact factor: 3.575

4.  Gonadal and extragonadal expression of inhibin alpha, beta A, and beta B subunits in various tissues predicts diverse functions.

Authors:  H Meunier; C Rivier; R M Evans; W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

5.  Ovarian aging and bone metabolism in menstruating women aged 35-50 years.

Authors:  Fisun Vural; Birol Vural; Izzet Yucesoy; Selim Badur
Journal:  Maturitas       Date:  2005-10-16       Impact factor: 4.342

Review 6.  Molecular bases of the sympathetic regulation of bone mass.

Authors:  Shu Takeda; Gerard Karsenty
Journal:  Bone       Date:  2008-01-26       Impact factor: 4.398

7.  Female reproductive aging is marked by decreased secretion of dimeric inhibin.

Authors:  C K Welt; D J McNicholl; A E Taylor; J E Hall
Journal:  J Clin Endocrinol Metab       Date:  1999-01       Impact factor: 5.958

8.  Serum concentrations of dimeric inhibins, activin A, gonadotrophins and ovarian steroids during the menstrual cycle in older women.

Authors:  S Muttukrishna; T Child; G M Lockwood; N P Groome; D H Barlow; W L Ledger
Journal:  Hum Reprod       Date:  2000-03       Impact factor: 6.918

9.  Effects of activin A/erythroid differentiation factor on erythroid and megakaryocytic differentiations of mouse erythroleukemia (Friend) cells: evidence for two distinct modes of cell response.

Authors:  K Okafuji; K Kaku; M Seguchi; H Tanaka; Y Azuno; T Kaneko
Journal:  Exp Hematol       Date:  1995-03       Impact factor: 3.084

10.  Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.

Authors:  T Sugatani; U M Alvarez; K A Hruska
Journal:  J Cell Biochem       Date:  2003-09-01       Impact factor: 4.429

View more
  21 in total

Review 1.  Signaling pathways affecting skeletal health.

Authors:  Pierre J Marie
Journal:  Curr Osteoporos Rep       Date:  2012-09       Impact factor: 5.096

Review 2.  Reproductive hormones and bone.

Authors:  Kristy M Nicks; Tristan W Fowler; Dana Gaddy
Journal:  Curr Osteoporos Rep       Date:  2010-06       Impact factor: 5.096

3.  Loss of BMPR2 leads to high bone mass due to increased osteoblast activity.

Authors:  Jonathan W Lowery; Giuseppe Intini; Laura Gamer; Sutada Lotinun; Valerie S Salazar; Satoshi Ote; Karen Cox; Roland Baron; Vicki Rosen
Journal:  J Cell Sci       Date:  2015-02-06       Impact factor: 5.285

4.  Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production.

Authors:  Rodrigo D A M Alves; Marco Eijken; Karel Bezstarosti; Jeroen A A Demmers; Johannes P T M van Leeuwen
Journal:  Mol Cell Proteomics       Date:  2013-06-17       Impact factor: 5.911

5.  Association of SMAD2 polymorphisms with bone mineral density in postmenopausal Korean women.

Authors:  B-J Kim; J-Y Hwang; B-G Han; J-Y Lee; J Y Lee; E K Park; S H Lee; Y-E Chung; G S Kim; S-Y Kim; J-M Koh
Journal:  Osteoporos Int       Date:  2010-10-30       Impact factor: 4.507

6.  Decreased bone mineral density in rats rendered follicle-deplete by an ovotoxic chemical correlates with changes in follicle-stimulating hormone and inhibin A.

Authors:  A L Lukefahr; J B Frye; L E Wright; S L Marion; P B Hoyer; J L Funk
Journal:  Calcif Tissue Int       Date:  2012-01-17       Impact factor: 4.333

7.  Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.

Authors:  Youngjae Jeong; Salah A Daghlas; Yixia Xie; Molly A Hulbert; Ferris M Pfeiffer; Mark R Dallas; Catherine L Omosule; R Scott Pearsall; Sarah L Dallas; Charlotte L Phillips
Journal:  J Bone Miner Res       Date:  2018-06-22       Impact factor: 6.741

8.  Activin A inhibits RANKL-mediated osteoclast formation, movement and function in murine bone marrow macrophage cultures.

Authors:  Tristan W Fowler; Archana Kamalakar; Nisreen S Akel; Richard C Kurten; Larry J Suva; Dana Gaddy
Journal:  J Cell Sci       Date:  2015-01-20       Impact factor: 5.285

9.  Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment.

Authors:  A D Anastasilakis; S A Polyzos; P Makras; A Gkiomisi; M Savvides; A Papatheodorou; E Terpos
Journal:  Osteoporos Int       Date:  2012-11-03       Impact factor: 4.507

Review 10.  Receptor binding competition: A paradigm for regulating TGF-β family action.

Authors:  Erik Martinez-Hackert; Anders Sundan; Toril Holien
Journal:  Cytokine Growth Factor Rev       Date:  2020-10-06       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.